Diagnosis and management of AML in adults: 2017 ELN

The first edition of the European LeukemiaNet ELN recommendations for diagnosis and management of acute myeloid leukemia AML in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML, Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for

Diagnosis and management of AML in adults: 2017 ELN

Introduction, In 2010, an international expert panel, on behalf of the European LeukemiaNet ELN, published recommendations for diagnosis and management of acute myeloid leukemia AML, 1 These recommendations have been widely adopted in general practice, within clinical trials, and by regulatory agencies, During recent years, considerable progress has been made in understanding …

Diagnosis and management of AML in adults: 2017 ELN

Fichier PDF

egory based on MRD status, and criteria for progressive disease, Blood, 2017; 1294:424-447 Introduction In 2010, an international expert panel, on behalf of the European LeukemiaNet ELN, published recommendations for diagnosis and management of acute myeloid leukemia AML, 1 These recommen-dations have been widely adopted in general practice, within clinical trials, and by …

Validation of the 2017 European LeukemiaNet classification

Background: The revised 2017 European LeukemiaNet ELN classification ELN-2017 of acute myeloid leukemia AML divides patients into 3 prognostic risk categories, with additional factors such as the fms-like tyrosine kinase 3 FLT3-internal tandem duplication ITD allele ratio AR considered for risk stratification, To the best of the authors’ knowledge, the prognostic usefulness of ELN

AML Response Criteria

8 lignesThe criteria are as follows: Complete donor chimerism ≥ 95% donor chimerism …

DATEADD/REMOVE/MODIFYDESCRIPTION

4/14/2021	Add	Transfusion independent clarification
10/1/2020	Remove	The response criteria for CR and CRi were
10/1/2020	Add	Clarification was added to the For
7/7/2020	Modify	Updated guidance on how to report disease

Voir les 8 lignes sur www,cibmtr,org

Validation of the 2017 European LeukemiaNet classification

The European LeukemiaNet ELN first recommended a risk classification system in 2010 ELN-2010 in patients with AML, that integrated cytogenetic and molecular data, 5 Since then, further advances in our understanding of the genomic landscape and the application of improved assays for genetic testing have led to the development of prognostic models incorporating molecular data with …

Acute myeloid leukemia: 2019 update on risk‐stratification

Patients with CBF AML ELN favorable rarely have FLT3 aberrations Figure 1 and whether any such patients should receive both GO and midostaurin is hard to decipher absent more data; the same is true for the larger group of ELN intermediate patients with a FLT3 aberration, A lack of data makes it difficult to know whether midostaurin should be administered to all patients, as suggested by

ELN Recommendations

Revised response criteria for polycythemia vera and essential thrombocythemia: a ELN and IWG-MRT consensus project, Barosi et al,, Blood, 2013 Jun 6;12123:4778-81, Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale,

European LeukemiaNet 2020 recommendations for treating

33 ELN Foundation, Weinheim, Germany, hehlmann,eln@gmail,com, PMID: 32127639 PMCID: PMC7214240 DOI: 10,1038/s41375-020-0776-2 Abstract The therapeutic landscape of chronic myeloid leukemia CML has profoundly changed over the past 7 years, Most patients with chronic phase CP now have a normal life expectancy, Another goal is achieving a stable deep molecular response …

European LeukemiaNet 2020 recommendations for treating

The ELN panel for recommendations in CML comprises 34 experts from Europe, America, and the Asian-Pacific areas, The panel met six times at international meetings of …